JPS6019740B2 - Prostaglandin heat-stabilized composition - Google Patents

Prostaglandin heat-stabilized composition

Info

Publication number
JPS6019740B2
JPS6019740B2 JP52042639A JP4263977A JPS6019740B2 JP S6019740 B2 JPS6019740 B2 JP S6019740B2 JP 52042639 A JP52042639 A JP 52042639A JP 4263977 A JP4263977 A JP 4263977A JP S6019740 B2 JPS6019740 B2 JP S6019740B2
Authority
JP
Japan
Prior art keywords
prostaglandin
heat
amylose
stabilized composition
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP52042639A
Other languages
Japanese (ja)
Other versions
JPS53130417A (en
Inventor
洋彦 清水
憲明 上西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to JP52042639A priority Critical patent/JPS6019740B2/en
Publication of JPS53130417A publication Critical patent/JPS53130417A/en
Publication of JPS6019740B2 publication Critical patent/JPS6019740B2/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins

Description

【発明の詳細な説明】 本発明はプロスタグランジン熱安定化組成物に関するも
のである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to prostaglandin heat stabilizing compositions.

本発明において、生物活性プロスタグランジンとは生体
中に存在することが証明されている炭素数20のブロス
タン酸を基本骨格とする一群の生理活性物質、例えばプ
ロスタグラ・ンジンA,(PGA,),プロスタグラン
ジンん(PGA2),プロスタグランジンE,(PGE
,),プロスタグランジンE2(POE2),プロスタ
グランジンF,Q(PGF2Q),及びプロスタグラン
ジンF2Q(PGF2Q)なとまたはそれらの謙導体で
ある。
In the present invention, bioactive prostaglandins are a group of physiologically active substances whose basic skeleton is brostanic acid with 20 carbon atoms, which has been proven to exist in living organisms, such as prostaglandin A, (PGA,), Prostaglandin (PGA2), Prostaglandin E, (PGE
, ), prostaglandin E2 (POE2), prostaglandin F, Q (PGF2Q), and prostaglandin F2Q (PGF2Q), or their humble conductors.

これらの化合物は徴量で陣痛誘発作用、胃酸分泌抑制作
用、血圧降下作用、抗ぜん息作用などの種々の薬理作用
を示し、医薬としての反応が期待され、開発が進められ
ている。
These compounds exhibit various pharmacological effects such as labor induction, gastric acid secretion suppressing, blood pressure lowering, and anti-asthmatic effects, and are expected to have a medicinal effect and are being developed.

しかしながらプロスタグランジンは一般に不安定な化合
物で、酸,アルカリ、熱に対して非常に分解し易い性質
を有している。
However, prostaglandins are generally unstable compounds and are highly susceptible to decomposition by acids, alkalis, and heat.

室温に保存した場合には数週間後には分解生成物が認め
られ、高温例えば100午0に加熱すると数時間でその
大半が分解する。
When stored at room temperature, decomposition products are observed after several weeks, and when heated to a high temperature, for example, 100:00, most of them decompose within several hours.

また低い温度、例えば冷蔵庫内に保存した場合でも徐々
に分解することが知られている。特にPGE類は下に示
すように5員環部分で脱水反応が起り易く、医薬として
用いるにはこのような分解を抑制し、安定な製剤を得る
ことが必須の課題である。
It is also known that it gradually decomposes even when stored at low temperatures, for example in a refrigerator. In particular, PGEs are prone to dehydration reactions at the 5-membered ring moiety as shown below, and in order to be used as medicines, it is essential to suppress such decomposition and obtain stable preparations.

本発明者らはこのような観点から種々の水浴性高分子化
合物の安定化作用を詳細に検討した結果、高分子化合物
の種類によって安定化作用が著しく異なることに気付い
た。
The present inventors have studied in detail the stabilizing effects of various water bathing polymer compounds from this perspective, and have found that the stabilizing effects vary significantly depending on the type of polymer compound.

例えばポリアクリル酸,ポリグルタミン酸,アルギン酸
,ペクチン,ポリエチレンィミンなどは、PGE類を安
定化する作用はなく、グアヤビーンガム,ロカストビー
ンガム,アラビアゴム,トラガント末,寒天,ィヌリン
などは安定化作用は認められるが、効力は弱い。ところ
が全く意外にもグルコースのQ−1,4結合からなる直
鎖状高分子であるアミロースはPGE類を安定化する作
用は弱いが、ァミロースを酵素分解したものまたはヒド
ロキシェチル化或いはカルボキシメチル化した化学修飾
アミロース及びそれらを加水分解酵素アミラーゼで処理
したものは顕著な熱安定化作用を示すことがわかつた。
一方、グルコースのQ−1,4結合とQ−1,6結合か
らなる分岐性高分子化合物であるアミロベクチンは、そ
のま)でも或いはアミラーゼ処理をしたものでも明らか
な安定化作用を示すことを見出して本発明を完成するに
いたつた。即ち、本発明は、生物活性プロスタグランジ
ンと、ヒドロキシエチルアミロース、力ルポキシメチル
アミロース、アミロベクチンおよびそれらの加水分解酵
素処理物ならびに酵素分解アミロースからなる群から選
ばれる少なくとも一種とを混合してなるプロスタグラン
ジン熱安定化組成物に関する。これらの素材は市販品と
して容易に入手可能なもの、および自体公知の方法で容
易に調製しうるものである。
For example, polyacrylic acid, polyglutamic acid, alginic acid, pectin, polyethyleneimine, etc. have no stabilizing effect on PGEs, and guaya bean gum, locust bean gum, gum arabic, powdered tragacanth, agar, inulin, etc. have no stabilizing effect. It is recognized, but its effectiveness is weak. However, completely unexpectedly, amylose, a linear polymer consisting of Q-1,4 bonds of glucose, has a weak stabilizing effect on PGEs, but it is not possible to use enzyme-degraded amylose, hydroxyethylated or carboxymethylated amylose. It was found that chemically modified amylose and those treated with the hydrolytic enzyme amylase exhibited a remarkable thermostabilizing effect.
On the other hand, it was discovered that amylobectin, a branched polymer compound consisting of Q-1,4 and Q-1,6 bonds of glucose, exhibits a clear stabilizing effect when used as is or after being treated with amylase. As a result, we have completed the present invention. That is, the present invention provides a mixture of bioactive prostaglandin and at least one member selected from the group consisting of hydroxyethyl amylose, poxymethyl amylose, amylovectin, hydrolytic enzyme-treated products thereof, and enzymatically decomposed amylose. The present invention relates to prostaglandin heat stabilizing compositions. These materials are easily available as commercial products and can be easily prepared by methods known per se.

本発明組成物の製造は、好ましくはまず上記素材をブロ
スタグランジンの1にたいして通常重量比で10〜10
00となるようにし、それを水に溶解または懸濁させる
Preferably, the composition of the present invention is manufactured by first adding the above-mentioned materials to 1 part of brostaglandin in a normal weight ratio of 10 to 10 parts.
00 and dissolve or suspend it in water.

この時、溶解いこくい場合は懸濁液を加塩するか、0.
05〜0.1Nのカ性ソーダ水溶液に一度溶解後、酢酸
または塩酸のような適当な酸を加えて、pH4〜7に調
節してもよい。ついでプロスタグランジンまたはその塩
を結晶,粉末,或いは水またはアルコール,アセトンの
ような樋性有機溶媒の溶液等として加え、よく均一に混
合する。これを減圧乾燥または凍結乾燥などの処理を施
して、水分を除去することによって熱安定なプロスタグ
ランジン組成物である乾燥粉末が得られ、注射剤または
錠剤などの製剤とすることができる。その際、水分の除
去はなるべく完全に行うことが望ましい。
At this time, if it is difficult to dissolve, add salt to the suspension, or add 0.0% salt to the suspension.
Once dissolved in a 05-0.1N caustic soda aqueous solution, a suitable acid such as acetic acid or hydrochloric acid may be added to adjust the pH to 4-7. Next, prostaglandin or a salt thereof is added as a crystal, powder, or a solution in water, alcohol, or a liquid organic solvent such as acetone, and mixed thoroughly and uniformly. By subjecting this to a treatment such as vacuum drying or freeze drying to remove water, a dry powder, which is a heat-stable prostaglandin composition, is obtained, which can be made into a preparation such as an injection or a tablet. At this time, it is desirable to remove moisture as completely as possible.

また、必要に応じて通常用いられる増量剤,藤形剤,崩
壊剤,或いは等張化剤,防腐剤,悪癖化剤などを用いる
ことができる。また薬効を呈しない量のビタミンC,グ
ルタチオン,ビタミンEなどの抗酸化剤を用いることも
できる。
Further, if necessary, commonly used fillers, turquoise agents, disintegrants, tonicity agents, preservatives, habit-stimulating agents, etc. can be used. It is also possible to use antioxidants such as vitamin C, glutathione, and vitamin E in amounts that do not exhibit medicinal effects.

以下、実施例によって詳しく説明する。A detailed explanation will be given below using examples.

その際、プロスタグランジンの分解の程度は、1000
0で一定時間開放系で加熱した後で、残存するプロスタ
グランジンを酸性でクロロホルム抽出し、その一定量を
シリカゲルプレートにスポットして酢酸エチル:ィソオ
クタン:酢酸:水(110:50:20:100)の上
層で展開し、10%硫酸アンモニウムを含む2%硫酸水
溶液を均一に噴露した後180qo、1〜2時間加熱発
色し、その強度を島津デンシトメーターCP−900を
用いて測定し、同一プレート上の標準プロスタグランジ
ンの検量線から定量した。
At that time, the degree of prostaglandin decomposition is 1000
After heating in an open system for a certain period of time at 0, the remaining prostaglandins were extracted with acidic chloroform, a certain amount of which was spotted on a silica gel plate and extracted with ethyl acetate:isooctane:acetic acid:water (110:50:20:100). ), and after uniformly spraying a 2% aqueous sulfuric acid solution containing 10% ammonium sulfate, the color was developed by heating at 180 qo for 1 to 2 hours, and the intensity was measured using a Shimadzu densitometer CP-900. Quantification was determined from a standard prostaglandin calibration curve on the plate.

実施例 1 酵素分解ァミロース,ヒドロキシヱチルアミロースまた
はカルボキシメチルアミロースを別々に40の9とり、
水1地を加えて溶かす。
Example 1 Enzymatically decomposed amylose, hydroxyethyl amylose or carboxymethyl amylose were separately taken as 9 out of 40,
Add one drop of water and dissolve.

これにPGE2を200仏夕加え、凍結乾燥後100℃
で7時間加熱し、残存する量を側定した結果を表2に示
す。表1実施例 2 アミロベクチンを水に分散して2%懸濁液とし、100
℃に加熱する。
Add 200 grams of PGE2 to this and freeze dry at 100°C.
Table 2 shows the results of heating for 7 hours and determining the amount remaining. Table 1 Example 2 Amylobectin was dispersed in water to make a 2% suspension, and 100%
Heat to ℃.

冷却液1地をとりPCE2200〃夕とまぜ凍結乾燥し
て100oo、7時間加熱する。残存するE2を測定し
た結果41%であった。
Take one coolant, mix with PCE2200, freeze-dry, and heat at 100 oo for 7 hours. The residual E2 was measured and found to be 41%.

ヒドロキシェチルでん粉の4%水溶液を0.5泌,1.
0の【及び2のととり、それぞれにプロスタグランジン
E2200仏夕とF2Q200山夕を加え、混合後凍結
乾燥し、10000、7時間処理後の残存率を表3に示
す。表3 実施例 3 アミロベクチンとプロスタグランジンE2を重量比で2
00/1となるよう水溶液で混合し凍結乾燥後1000
0、7時間加熱後の残存率を調べた。
Add 0.5% 4% aqueous solution of hydroxyethyl starch, 1.
Prostaglandin E2200 Butsu and F2Q200 Sanyu were added to No. 0 and No. 2, respectively, and after mixing, freeze-drying was carried out, and the residual rate after 7 hours treatment with 10000 was shown in Table 3. Table 3 Example 3 Amylobectin and prostaglandin E2 in weight ratio of 2
Mix with aqueous solution so that the ratio is 00/1 and freeze-dry it to 1000
The residual rate after heating for 0 and 7 hours was investigated.

対照としてプ。スタグランジンと包援化合物を形成して
安定化作用を示すことが知られている8−シクロデキス
トリンを用いて、同様に処理し残存するPGE2を測定
した結果、アミロベクチンでは79%、3−シクロデキ
ストリンでは56%であった。比較例 1各素材50の
9を水1奴に溶かし、ブロスタグランジンE21の夕を
加えて麓拝後、凍結乾燥し、10500で1時間および
7時間加熱した時の残存PGE2量を測定した結果を表
2に示す。
Pu as a control. Using 8-cyclodextrin, which is known to form an inclusion compound with staglandin and exhibit a stabilizing effect, the remaining PGE2 was measured in the same manner, and it was 79% for amylobectin and 79% for 3-cyclodextrin. It was 56%. Comparative Example 1 9 of 50 of each material was dissolved in 1 cup of water, brostaglandin E21 was added thereto, lyophilized, and the remaining amount of PGE2 was measured when heated at 10500 for 1 hour and 7 hours. The results are shown in Table 2.

表2Table 2

Claims (1)

【特許請求の範囲】[Claims] 1 生物活性プロスタグランジンと、ヒドロキシエチル
アミロース、カルボキシメチルアミロース、アミロペク
チンおよびそれらの加水分解酵素処理物ならびに酵素分
解アミロースからなる群から選ばれる少なくとも一種と
を混合してなるプロスタグランジン熱安定化組成物。
1. A prostaglandin heat-stabilizing composition formed by mixing a biologically active prostaglandin with at least one member selected from the group consisting of hydroxyethyl amylose, carboxymethyl amylose, amylopectin, hydrolytic enzyme-treated products thereof, and enzymatically decomposed amylose. thing.
JP52042639A 1977-04-15 1977-04-15 Prostaglandin heat-stabilized composition Expired JPS6019740B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP52042639A JPS6019740B2 (en) 1977-04-15 1977-04-15 Prostaglandin heat-stabilized composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP52042639A JPS6019740B2 (en) 1977-04-15 1977-04-15 Prostaglandin heat-stabilized composition

Publications (2)

Publication Number Publication Date
JPS53130417A JPS53130417A (en) 1978-11-14
JPS6019740B2 true JPS6019740B2 (en) 1985-05-17

Family

ID=12641572

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52042639A Expired JPS6019740B2 (en) 1977-04-15 1977-04-15 Prostaglandin heat-stabilized composition

Country Status (1)

Country Link
JP (1) JPS6019740B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3304864A1 (en) * 1983-02-12 1984-08-16 Bayer Ag, 5090 Leverkusen Adsorbates of prostaglandins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52143217A (en) * 1976-05-21 1977-11-29 Yamanouchi Pharmaceut Co Ltd Stable composition containing prostaglandi ne

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52143217A (en) * 1976-05-21 1977-11-29 Yamanouchi Pharmaceut Co Ltd Stable composition containing prostaglandi ne

Also Published As

Publication number Publication date
JPS53130417A (en) 1978-11-14

Similar Documents

Publication Publication Date Title
JPS58164683A (en) Stabilized solid composition
JPS6054322B2 (en) Manufacturing method for molded products
US4150110A (en) Coated granules of polyacrylic alkali metal salts and method of producing same
JPS6310686B2 (en)
US3027229A (en) Method of preparing hydrated calcium phosphate gels
US4073931A (en) Nitroglycerine inclusion compounds with cyclodextrin and composition containing same
US2967802A (en) Hydrated calcium phosphate gelantigen composition and method of preparing same
TW565565B (en) Crystalline amrubicin hydrochloride
JP2563187B2 (en) Method for producing calcium phosphate-based cured product
JPS6019740B2 (en) Prostaglandin heat-stabilized composition
JPH02100695A (en) Production of indigestible dextrin
EP0088958B1 (en) Stabilization of azulene derivatives
JPH0677598B2 (en) COMPOSITE COMPOSITION FOR PRODUCING CALCIUM PHOSPHATE-BASED CURED BODY AND METHOD FOR PRODUCING CURED BODY
JPS6019742B2 (en) Prostaglandin heat-stabilized composition
RO109649B1 (en) Inclusion complexes of n-etoxicabonyl-3-morpholino-sydnonimine and preparation processes therefor
US2791532A (en) Solubilized adrenochrome hemostatic compositions and process of producing same
JPH02275812A (en) Liquid agent for hardened calcium phosphate and hardened material produced by using the agent
CA1075230A (en) Process for preparing solid sodium amoxycillin
JPS6019290B2 (en) Prostaglandin heat-stabilized composition
EP0719286B1 (en) Dextran esters, process for producing them and their use for encasing and encapsulating medicaments
EP0318906B1 (en) Lyophilized preparation of platinum compound
DE2259151A1 (en) PROCESS FOR MANUFACTURING ANTIBIOTIC DERIVATE
US2928849A (en) High-molecular weight derivatives of steroids containing hydroxyl groups and method of producing the same
JPS6019741B2 (en) Prostaglandin heat-stabilized composition
US2830932A (en) N,n'dibenzylethylene diamine salt of heparin